BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27901491)

  • 1. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
    Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
    Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
    Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
    Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
    Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.
    Wang L; Xia ZJ; Huang HQ; Lu Y; Zhang YJ
    Int J Hematol; 2012 Nov; 96(5):617-23. PubMed ID: 22983648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
    Kwong YL; Kim SJ; Tse E; Oh SY; Kwak JY; Eom HS; Do YR; Mun YC; Lee SR; Shin HJ; Suh C; Chuang SS; Lee YS; Lim ST; Izutsu K; Suzuki R; Relander T; d'Amore F; Schmitz N; Jaccard A; Kim WS
    Ann Oncol; 2018 Jan; 29(1):256-263. PubMed ID: 29077846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.
    Ma HH; Qian LT; Pan HF; Yang L; Zhang HY; Wang ZH; Ma J; Zhao YF; Gao J; Wu AD
    Med Oncol; 2010 Sep; 27(3):798-806. PubMed ID: 19685292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
    Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I
    Wang HY; Niu SQ; Yang YY; Li YY; Chen HB; Zhang YJ
    Cancer Med; 2018 Dec; 7(12):5863-5869. PubMed ID: 30484966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
    Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
    Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.
    Li J; Li Y; Zhong M; Liu X; Song Y; Li J; Li K; Yi P
    Med Sci Monit; 2018 May; 24():2683-2692. PubMed ID: 29712887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy and prognosis analysis of 47 patients with extranodal NK/T-cell lymphoma].
    Zhang SS; Wei M; Li HH; Jing Y; Li F; Huang WR; Lu XL; Liu ZX; Zhou Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):119-23. PubMed ID: 21362235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
    Tsai HJ; Lin SF; Chen CC; Chen TY; Su WC; Hwang WL; Lin JC; Chiou TJ; Kao WY; Chiu CF; Chang YF; Chang JS; Chang MC; Su IJ
    Eur J Haematol; 2015 Feb; 94(2):130-7. PubMed ID: 24957163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.